Turning Point Therapeutics (NASDAQ:TPTX) had its target price hoisted by HC Wainwright from $100.00 to $130.00 in a research note issued to investors on Monday, The Fly reports. HC Wainwright currently has a buy rating on the stock.
TPTX has been the subject of a number of other reports. Zacks Investment Research upgraded Turning Point Therapeutics from a hold rating to a buy rating and set a $134.00 price target for the company in a research note on Thursday, October 15th. BidaskClub lowered shares of Turning Point Therapeutics from a strong-buy rating to a buy rating in a research report on Thursday, October 22nd. Roth Capital reissued a buy rating and issued a $77.00 price objective (up from $75.00) on shares of Turning Point Therapeutics in a research note on Wednesday, August 19th. SVB Leerink raised their price target on Turning Point Therapeutics from $77.00 to $116.00 and gave the stock an outperform rating in a research note on Monday. Finally, Canaccord Genuity raised their price objective on Turning Point Therapeutics from $80.00 to $85.00 and gave the company a buy rating in a research note on Friday, August 21st. Eight analysts have rated the stock with a buy rating, The stock has an average rating of Buy and an average price target of $118.86.
Shares of NASDAQ TPTX opened at $101.28 on Monday. The company has a market cap of $4.27 billion, a PE ratio of -27.23 and a beta of 1.30. Turning Point Therapeutics has a 12 month low of $31.30 and a 12 month high of $122.85. The company has a 50-day simple moving average of $94.39 and a 200-day simple moving average of $70.10.
Large investors have recently made changes to their positions in the stock. FMR LLC grew its stake in shares of Turning Point Therapeutics by 18.2% during the second quarter. FMR LLC now owns 5,079,197 shares of the company’s stock worth $328,066,000 after buying an additional 780,559 shares during the last quarter. Vanguard Group Inc. grew its stake in Turning Point Therapeutics by 33.3% in the second quarter. Vanguard Group Inc. now owns 2,783,183 shares of the company’s stock valued at $179,765,000 after acquiring an additional 695,062 shares during the period. State Street Corp boosted its position in shares of Turning Point Therapeutics by 3.5% during the first quarter. State Street Corp now owns 1,068,714 shares of the company’s stock valued at $47,729,000 after buying an additional 36,063 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Turning Point Therapeutics by 0.9% during the second quarter. Jennison Associates LLC now owns 634,504 shares of the company’s stock valued at $40,983,000 after buying an additional 5,756 shares during the last quarter. Finally, Federated Hermes Inc. lifted its holdings in Turning Point Therapeutics by 43.1% during the second quarter. Federated Hermes Inc. now owns 607,082 shares of the company’s stock worth $39,211,000 after acquiring an additional 182,972 shares during the period. 87.33% of the stock is currently owned by institutional investors and hedge funds.
Turning Point Therapeutics Company Profile
Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Further Reading: Hedge Funds – Risk or Reward?
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.